Harari S, et al. - Nintedanib's therapeutic impact was assessed in patients with severe idiopathic pulmonary fibrosis (IPF). The decline in lung function before and after treatment, as well as patient survival after 6 months of nintedanib therapy, was assessed in patients with severe IPF. The rate of decline of absolute and % predicted diffusing capacity of the lung for carbon monoxide (D_LCO) was slowed down by nintedanib, however, it failed to demonstrate a significant impact on forced vital capacity or other lung parameters. One-year survival of 79%, calculated from month 6 of therapy with nintedanib, was noted.